October 2024 – Page 297 – Get News Story

Hemophilia B Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, MOA and ROA by DelveInsight | Novo Nordisk, Sanofi, Pfizer, Belief BioMed, Centessa Pharmaceuticals

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Hemophilia B pipeline constitutes 15+ key companies continuously working towards developing 20+ Hemophilia B treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Hemophilia B Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hemophilia B Market.

The Hemophilia B Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Hemophilia B Pipeline Report

Companies across the globe are diligently working toward developing novel Hemophilia B treatment therapies with a considerable amount of success over the years. Hemophilia B Key players such as – Belief Biomed, ISU ABXIS, TiumBio, Be Biopharma, Regeneron Pharmaceuticals, Pfizer, Biocad, CSL Behring, Shanghai Vitalgen BioPharma, Baxalta, Amarna therapeutics, Catalyst Biosciences, Freeline Therapeutics, Belief BioMed, Centessa Pharmaceuticals, Novo Nordisk, Sanofi, Pfizer, and others are developing therapies for the Hemophilia B treatment

Hemophilia B Emerging therapies such as – BBM-H901, ISU304, TU7710, BE-101, REGV131, PF-06838435, ANB-002, AAV5-hFIXco-Padua, VGB-R04, AskBio009, AMA005, CB 2679d-GT, FLT180a, BBM-H901, SerpinPC, Concizumab, Fitusiran, PF-06, and others are expected to have a significant impact on the Hemophilia B market in the coming years.
In July 2024, CSL Behring has reported the treatment of two patients with HEMGENIX (etranacogene dezaparvovec) gene therapy for haemophilia B, a hereditary bleeding condition. The treatments were administered at haemophilia centres in France. HEMGENIX underwent extensive clinical development led by UniQure, with CSL Behring assuming sponsorship of the trials after acquiring global commercial rights to the therapy.

Hemophilia B Overview

Hemophilia B is a rare genetic bleeding disorder in which affected individuals have insufficient blood protein levels called factor IX. Hemophilia B, also known as factor IX deficiency or Christmas disease, is the second most common type of hemophilia. Factor IX is a clotting factor. Clotting factors are specialized proteins needed for blood clotting, the process by which blood seals a wound to stop bleeding and promote healing. Individuals with hemophilia B do not bleed faster than unaffected individuals, they bleed longer.

To know more about the Hemophilia B pipeline report, click here:

https://www.delveinsight.com/report-store/hemophilia-b-pipeline-insight

Hemophilia B Pipeline Therapies along with Key Players:

BBM-H901: Belief Biomed
ISU304: ISU ABXIS
TU7710: TiumBio
BE-101: Be Biopharma
REGV131: Regeneron Pharmaceuticals
PF-06838435: Pfizer
ANB-002: Biocad
AAV5-hFIXco-Padua: CSL Behring
VGB-R04: Shanghai Vitalgen BioPharma
AskBio009: Baxalta
AMA005: Amarna therapeutics
CB 2679d-GT: Catalyst Biosciences
FLT180a: Freeline Therapeutics
BBM-H901: Belief BioMed
SerpinPC: Centessa Pharmaceuticals
Concizumab: Novo Nordisk
Fitusiran: Sanofi
PF-06741086: Pfizer

Hemophilia B Pipeline Therapeutics Assessment

The Hemophilia B Pipeline report proffers an integral view of the Hemophilia B emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration.

Hemophilia B Pipeline Clinical Phases:

DelveInsight’s Report covers around 20+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Further Hemophilia B product details are provided in the report. Download the Hemophilia B pipeline report to learn more about the emerging Hemophilia B therapies

Some of the key companies in the Hemophilia B Therapeutics Market include:

Key companies developing therapies for Hemophilia B treatment are – Aptevo, Bayer, BioMarin, Catalyst Biosciences, CSL Behring, GC Pharma, Kaifeng Pharmaceutical, KM Biologics, LFB, Novo Nordisk, Pfizer, Octapharma, Roche, Sanofi, SinoCelltech, Spark Therapeutics, Takeda, UniQure, and others.

Hemophilia B Pipeline Analysis:

The report provides insights into

The report provides detailed insights about companies that are developing therapies for the Hemophilia B treatment with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hemophilia B Treatment.
Hemophilia B key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Hemophilia B Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hemophilia B market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Hemophilia B Pipeline Market Drivers

Increasing prevalence of Hemophilia B disease
Increasing R&D on identifying new therapeutic agents

Hemophilia B Pipeline Market Barriers

High cost of Hemophilia B treatment

Download the Hemophilia B pipeline report to learn more about the emerging Hemophilia B therapies

Scope of Hemophilia B Pipeline Drug Insight

Coverage: Global
Key Hemophilia B Companies: Belief Biomed, ISU ABXIS, TiumBio, Be Biopharma, Regeneron Pharmaceuticals, Pfizer, Biocad, CSL Behring, Shanghai Vitalgen BioPharma, Baxalta, Amarna therapeutics, Catalyst Biosciences, Freeline Therapeutics, Belief BioMed, Centessa Pharmaceuticals, Novo Nordisk, Sanofi, Pfizer, and others
Key Hemophilia B Therapies: BBM-H901, ISU304, TU7710, BE-101, REGV131, PF-06838435, ANB-002, AAV5-hFIXco-Padua, VGB-R04, AskBio009, AMA005, CB 2679d-GT, FLT180a, BBM-H901, SerpinPC, Concizumab, Fitusiran , PF-06, and others
Hemophilia B Therapeutic Assessment: Hemophilia B current marketed and Hemophilia B emerging therapies
Hemophilia B Market Dynamics: Hemophilia B market drivers and Hemophilia B market barriers

Get a Free Sample PDF Report to know more about Hemophilia B Pipeline Assessment

Table of Contents

1	Hemophilia B Report Introduction
2	Hemophilia B Executive Summary
3	Hemophilia B Overview
4	Hemophilia B- Analytical Perspective In-depth Commercial Assessment
5	Hemophilia B Pipeline Therapeutics
6	Hemophilia B Late Stage Products (Phase II/III)
7	Hemophilia B Mid Stage Products (Phase II)
8	Hemophilia B Early Stage Products (Phase I)
9	Hemophilia B Preclinical Stage Products
10	Hemophilia B Therapeutics Assessment
11	Hemophilia B Inactive Products
12	Company-University Collaborations (Licensing/Partnering) Analysis
13	Hemophilia B Key Companies
14	Hemophilia B Key Products
15	Hemophilia B Unmet Needs
16	Hemophilia B Market Drivers and Barriers
17	Hemophilia B Future Perspectives and Conclusion
18	Hemophilia B Analyst Views
19	Appendix
20	About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hemophilia B Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, MOA and ROA by DelveInsight | Novo Nordisk, Sanofi, Pfizer, Belief BioMed, Centessa Pharmaceuticals

Sheds for Sale Salem, Oregon Custom-Built Onsite by Family-Owned South River Structures for Storage, Workshops, and Other Uses

South River Structures is a local, family-owned business that builds sheds onsite. It uses quality materials and offers sheds in different dimensions to fulfill a client’s requirements. Shed styles include Inspiration, Santiam, Cascade, and Lofted Barn Style.

According to announcements released by South River Structures and Andy, the business builds sheds for sale Salem, Oregon. It constructs the sheds on site, using locally procured lumber. This local, family-owned business facilitates a stress-free shed design process. Buyers can easily configure a shed using the handy tool on the business’s website.

The built-to-order sheds Salem, Oregon are available in four different styles. These are Inspiration, Santiam, Cascade, and Lofted Barn.

With a focus on durability, functionality, and style, South River Structures aims to help homeowners maximize their outdoor space while adding an aesthetically pleasing structure to their property.

South River Structures emphasizes the value of having a well-built storage shed on residential properties. Whether intended for storing gardening tools, outdoor furniture, or seasonal equipment, these sheds effectively keep outdoor essentials organized and easily accessible. Designed to complement various home styles, the sheds offered by South River Structures serve as both functional and visually appealing additions to any property.

For homeowners seeking a versatile structure, the Inspiration Series offers a unique solution. This series features simple interior panels, allowing homeowners to customize the space based on their specific needs. Whether used as a workspace, creative studio, home gym, or relaxation area, the Inspiration Series sheds offer flexibility to cater to various personal preferences.

The Santiam Series from South River Structures stands out for its high level of customization. Designed with practicality and comfort in mind, the Santiam Series can be personalized with additional windows, doors, and even a porch, offering ample storage space and multiple access points. The design ensures it can function as a traditional storage shed or a multi-purpose space, depending on the homeowner’s requirements.

The Cascade Series is ideal for those needing a heavy-duty storage solution. Built using superior materials and designed to withstand the elements, the Cascade Series sheds are easy to install and highly durable, making them a convenient choice for those with varied storage needs. Homeowners benefit from a robust structure without the hassle of a complicated assembly process.

Another popular option, the Loft-Barn Series, brings a distinctive aesthetic to any property. Featuring the classic barn-style roof, these sheds offer abundant overhead space and a rustic charm that enhances the overall look of the outdoor area. The Loft-Barn Series sheds provide more than just storage; they become a beautiful and functional part of the home’s landscape, making them an eye-catching feature for passersby.

South River Structures takes pride in its commitment to quality and customer satisfaction. Expert storage shed builders work closely with clients to ensure the structure meets their specific requirements. From selecting the right size, features, and accessories to choosing the perfect color and style, every aspect of the shed is tailored to suit the individual property.

South River Structures ensures the sheds are built on a stable foundation as part of the installation process. A level gravel base is prepared for each shed, ensuring maximum stability and long-term durability. Homeowners also have the option to have South River Structures handle the construction of the base if desired.

Once the shed is completed, it is delivered directly to the homeowner’s property at no additional charge. This hassle-free delivery and installation process allows homeowners to enjoy their new storage space without added stress.

About the Company:

South River Structures, owned by brothers Andy and Dannie, builds sheds. The business serves Lebanon, Salem, Albany, Eugene, McMinnville, Corvallis, and Sweet Home. The business builds the finest sheds using quality materials and excellent craftsmanship. It treats every customer with respect and dignity.

Media Contact
Company Name: South River Structures
Contact Person: Andy
Email: Send Email
Phone: (541) 313-9143
Address:30920 Brownsville Rd
City: Lebanon
State: OR 97355
Country: United States
Website: https://srstructures.com/

Moving pets abroad with help from a Pet Transport Pro

Each year millions of people move their lives to another country. Whether for work, retirement, or a personal change, countless Americans are starting a new life abroad. Many Americans own pets, and relocating their pets inevitably becomes a part of their big move.

There are hundreds of companies offering international pet transport services on the internet, and they are essentially all doing the same thing. They are coordinating the travel of pets through third parties, and they are acting more as travel agents rather than actual pet movers. The person on the phone is actually not the person moving their pets at all. This person is simply making arrangements through third parties to get pets to their destination.

In a sea of endless companies offering these type of pet moving services, one company stands out above the rest by taking an entirely different approach and handling pet moves in a much more personalized way. That company is Pet Transport Pro, and their unique and personalized approach to moving their clients’ beloved family members has set a new standard of excellence for the industry.

Founded by Anthony Denicker, his approach to international pet travel shows his personal commitment to his clients and their pets from the very first phone call all the way through to their pets’ final destination. And if his 28 years of experience in the industry including a television series on Nat Geo Wild aren’t enough to convince his clients that Pet Transport Pro is the best in the business, his absolutely hands-on approach to moving their pets surely does.

“I don’t sleep at night when moving my clients’ pets. I feel personally responsible for them as if they were my own babies which is why I handle the moves myself… to make sure it’s done right.”

This hands-on approach guarantees Denicker at least 250 nights a year on the road away from his family. His average travel mileage is the equivalent of circling the globe over four times annually. While traveling from state to state personally handling his clients’ moves caps the amount of jobs Pet Transport Pro can do at one time, Denicker insists it will always be about quality over quantity.

“I compare it to buying a cake,” he explains, “Do you want your cake from Entenmann’s or do you want your cake from the best local bakery? I’ve always been a perfectionist,“ he adds.

Denicker’s approach to international pet relocation sets Pet Transport Pro apart from every other pet relocation company in the world because of the hands-on commitment which cannot be found anywhere else. When asked why he doesn’t just sub the work out like his competition, his answer is simple.

“Because I really care about my clients and their pets. The only way to truly ensure the wellbeing of my clients’ furry family members is by doing it myself. It is as much for my peace of mind as it is for theirs.”

He really is the Pet Transport Pro.

Media Contact
Company Name: Pet Transport Pro
Contact Person: Anthony Denicker
Email: Send Email
Phone: 844-738-7447
Country: United States
Website: https://pettransportpro.com/

Blogging Unplugged Publishes A Free Blog Setup Checklist

Experienced blogger Jasmeet Singh continues to expand the offerings on his blog. The latest update includes free access to a blog setup checklist.

Jasmeet Singh, founder of Blogging Unplugged, is pleased to announce the release of his free Blog Setup Checklist. This helpful tool for novices in the topic is a step-by-step list of actions to take for maximum effectiveness in boosting readership and increasing website revenues. The helpful blog was launched in 2022 and has continued to expand and add more features, tools, and recommendations.

Jasmeet authored the tutorials and articles that make up the blog’s content through his personal experience to conceptualize and implement his blog about blogging. The early content and articles available on the site begin with various tutorials at the most basic information level. The beginner is guided through the earliest steps of picking the blog topic, name, and web hosting company. Jasmeet identifies the necessary actions and offers recommendations about various services and products.

The tools used in the blog preparation are identified as part of the affiliate links. These tools currently include Kadence WP, Solid Security, HostPapa, ConvertKit, WP Rocket, and Semrush. Kadence WP allows for the creation of beautiful and fast-loading websites using Kadence Theme and Blocks.

The website can be secured with Solid Security, and attackers or hackers are kept at bay. Host Papa provides affordable and feature-rich web hosting plans backed by solid support. Convert Kit helps grow the website and engage readers using the email marketing tool. Thanks to the cache and performance optimization plugin, WP Rocket speeds up the website with just a few clicks. Semrush provides users with insights to expand organic traffic.

Additional details are available at https://bloggingunplugged.com/

Several recent blogs help expand knowledge and techniques for those looking to grow their web presence. Readers can learn ‘How to Add Images to a Collection in Kadence AI.’ Kadence AI was introduced in Kadence Blocks 3.2 and Starter Templates version 2.0.0. AI features were added to Kadence AI in Advanced Text Block, Design Library, and Starter Templates.

Kadence AI aims to quicken and simplify the website creation process. Users must provide basic information about the website and business, and Kadence AI will handle the rest. Using the customer’s inputs, Kadence AI will generate a library of templates and patterns that can be used with just one click to build the website from scratch. Kadence AI gives the owner complete control over design and generated content.

The latest blog covers how to add images to the Kadence AI collection. Additional tutorials or blog posts on Kadence include ‘How to Download Free Kadence Theme’ and ‘What’s New in Kadence Blocks 3.2 Update- New Features and Update’.

Three recent blog posts under the heading of Elementor are ‘How to Make a Container Clickable in Elementor,’ ‘What’s New in Elementor 3.7 Update – New Features and Improvements,’ and ‘How to Buy Elementor Pro Plugin.’

Two articles on WordPress are rounding out the list of recent Blogging Unplugged posts. These are ‘How to Install Other Language Packs For WordPress Dashboard’ and ‘How to Delete Sample Page in WordPress’.

Dozens of additional posts are on similar topics. Each article comes from Jasmeet Singh’s experience and skills. Jasmeet has over a decade of experience and has monetized his online efforts. He answers common questions associated with blogging that are neither simplistic nor overly complicated.

About the Company:

Jasmeet Singh continues to expand the list of topics available from Blogging Unplugged. The topics are written so beginners can understand and utilize them for conceptualizing and implementing a blog. The blog provides recommendations for tools and processes to enhance the creation and utilization of a monetized blog.

Media Contact
Company Name: Blogging Unplugged
Contact Person: Jasmeet Singh
Email: Send Email
Country: United States
Website: https://bloggingunplugged.com

Austin Commercial Roofing: Trusted for Unmatched Service Quality, Greater Austin Roofers Stand Out for Professionalism and Reliability

Greater Austin Roofers delivers expert commercial roofing services in Austin, offering high-quality installations, repairs, and maintenance with a focus on reliability and customer satisfaction.

Trusted for its top-tier roofing services, Greater Austin Roofers is a full-service company with over 30 years in the industry. Its unparalleled customer service, quality workmanship, and competitive pricing make it the go-to Austin commercial roofing contractor for roofing, guttering, and skylight services across the Austin area.

Greater Austin Roofers provides comprehensive services that cater to all roofing needs, from installation and full-roof replacement to repair, restoration, maintenance, and inspection for residential, commercial, or industrial properties. The company’s expertise in large-scale and small-scale projects has earned it a reputation for delivering exceptional results on time and within budget.

With a highly skilled team of licensed, bonded, and insured roofing experts who bring years of experience to every project, each job is undertaken with a commitment to high standards of workmanship and attention to detail. These expert roofers have the knowledge and experience to work with roofing materials of various types and styles, including asphalt shingles, metal roofs, cedar shakes, tile roofs, slate roofs, flat and low-sloped roofs, TPO, spray foam, and more.

The company has built a reputation for delivering tailored solutions for commercial roofing in Austin, catering to businesses of all sizes. From installations of new roofs to replacements and repairs, Greater Austin Roofers specializes in handling various commercial roofing systems, including metal, flat, TPO, and modified bitumen roofs.

For more information, visit https://www.greateraustinroofers.com/commercial-roofing-austin/

For businesses looking to upgrade their existing roof or construct a new commercial building, the company offers expert advice and seamless installation services using high-quality materials sourced from reputable manufacturers for durability and optimal performance. In addition, the team ensures that all roofing projects are completed within industry standards and local building codes, ensuring compliance and safety.

With its ability to offer custom roofing solutions, Greater Austin Roofers is synonymous with top-quality, long-lasting roofs and a one-stop solution for all commercial roofing needs in Austin.

Greater Austin Roofers complements its roofing expertise with roof maintenance services, providing the regular maintenance essential for extending the life of a roof and preventing costly damages. The company’s skilled technicians conduct thorough inspections to identify potential issues, such as leaks, structural weaknesses, or wear and tear.

Understanding that each roofing project has unique requirements, Greater Austin Roofers prioritizes close collaboration with clients, liaising closely with clients to deliver the best outcome and ensuring they receive clear, timely updates at every stage of the roofing process. This personalized approach ensures that every project meets the client’s budget, aesthetic preferences, and long-term goals.

For emergencies, the company is also known for its commitment to prompt emergency repair services. Whether severe weather or unexpected damage, the company provides swift emergency repair services to minimize disruption to business operations. The team is available to address urgent roofing needs, ensuring that commercial properties remain secure and protected during adverse conditions. This responsiveness sets Greater Austin Roofers apart from competitors, making it a reliable choice for businesses requiring fast, dependable roofing solutions.

Greater Austin Roofers continues to stand out as a premier choice for businesses seeking reliable, expert roofing services in Austin. The company’s commitment to high-quality materials, custom solutions, timely project completion, and responsive customer service makes it a trusted name in commercial roofing, delivering exceptional results across various industries to ensure businesses can rely on long-lasting roofs to protect their assets and operations for years.

About the Company:

Greater Austin Roofers is a trusted commercial and residential roofing company in Austin, Texas. The company specializes in roof installation, repair, and maintenance, handling various roofing systems, including metal, flat, and TPO roofs. Emphasizing high-quality materials, exceptional craftsmanship, and timely project completion, Greater Austin Roofers serves businesses of all sizes, delivering reliable and energy-efficient solutions. Its licensed and insured crew offers comprehensive services, including emergency repairs, ensuring protection and durability for every property. Greater Austin Roofers stands out for its commitment to excellence and customer satisfaction.

Media Contact
Company Name: Greater Austin Roofers
Contact Person: Bill S
Email: Send Email
Phone: +1 (737) 204-7821
Address:9204 Happy Trail
City: Austin
State: TX 78754
Country: United States
Website: https://www.greateraustinroofers.com/

Pompe Disease Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Market Dynamics, MOA, ROA by DelveInsight | M6P Therapeutics, Entrada Therapeutics, Maze Therapeutics, Astellas

Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Pompe Disease pipeline constitutes 15+ key companies continuously working towards developing 20+ Pompe Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Pompe Disease Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pompe Disease Market.

The Pompe Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Pompe Disease Pipeline Report:

Companies across the globe are diligently working toward developing novel Pompe Disease treatment therapies with a considerable amount of success over the years. Pompe Disease Key players such as – Asklepios Biopharmaceutical, GeneCradle Inc, Astellas Gene Therapies, Amicus Therapeutics, M6P Therapeutics, Entrada Therapeutics, Maze Therapeutics, Astellas Gene Therapies, Spark Therapeutics, and others, are developing therapies for the Pompe Disease treatment

Pompe Disease Emerging therapies such as – ACTUS-101, GC301, zocaglusagene nuzaparvovec, AT2221, M 021, GYS1 Knockdown Oligonucleotide, MZE 001, AT845, AAV2/8LSPhGAA, SPK-3006, Cipaglucosidase alfa, and others are expected to have a significant impact on the Pompe Disease market in the coming years.
In May 2024, Shionogi & Co., Ltd. (Osaka, Japan; CEO: Isao Teshirogi, Ph.D.) and Maze Therapeutics, Inc. (South San Francisco, California, USA; CEO: Jason Coloma, Ph.D.) have announced the completion of an exclusive global licensing agreement for MZE001. MZE001 is an investigational oral glycogen synthase 1 (GYS1) inhibitor designed to address Pompe disease by reducing the buildup of disease-causing glycogen.
In November 2023, Aro Biotherapeutics, a clinical-stage biotech company, has secured $41.5 million in a Series B funding round to further develop its lead candidate, ABX1100, for the treatment of Pompe disease. The round was led by Cowen Healthcare Investments, with participation from Series A investors including Northpond Ventures, Johnson & Johnson Innovation – JJDC, BVF Partners, and HealthCap.

Pompe Disease Overview

Pompe disease belongs to the ‘lysosomal storage disorders’ (LSDs) group of diseases. Within the cells, lysosomes are tiny compartments where all sorts of substances are recycled. By the action of digestive enzymes, the compounds are degraded. There are currently more than 50 different LSDs that are considered to be caused by the deficiency of one of these enzymes.

Get a Free Sample PDF Report to know more about Pompe Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/pompe-disease-pipeline-insight

Route of Administration

Pompe Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Molecule Type

Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Pompe Disease Pipeline Therapeutics Assessment

Pompe Disease Assessment by Product Type
Pompe Disease By Stage and Product Type
Pompe Disease Assessment by Route of Administration
Pompe Disease By Stage and Route of Administration
Pompe Disease Assessment by Molecule Type
Pompe Disease by Stage and Molecule Type

DelveInsight’s Pompe Disease Report covers around 20+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Some of the key companies in the Pompe Disease Therapeutics Market include:

Key companies developing therapies for Pompe Disease are – Spark Therapeutics, Amicus Therapeutics, Asklepios Biopharmaceutical, Audentes Therapeutics, Rocket Pharmaceuticals, Avidity Biosciences, AVROBIO, Maze Therapeutics, Denali Therapeutics, and others.

Emerging Pompe Disease Drugs Under Different Phases of Clinical Development Include:

ACTUS-101: Asklepios Biopharmaceutical
GC301: GeneCradle Inc
zocaglusagene nuzaparvovec: Astellas Gene Therapies
AT2221: Amicus Therapeutics
M 021: M6P Therapeutics
GYS1 Knockdown Oligonucleotide: Entrada Therapeutics
MZE 001: Maze Therapeutics
AT845: Astellas Gene Therapies
AAV2/8LSPhGAA: Asklepios Biopharmaceutical
SPK-3006: Spark Therapeutics
Cipaglucosidase alfa: Amicus Therapeutics

Download Sample PDF Report to know more about Pompe Disease drugs and therapies

Pompe Disease Pipeline Analysis:

The Pompe Disease pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Pompe Disease with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pompe Disease Treatment.
Pompe Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Pompe Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pompe Disease market.

Further Pompe Disease product details are provided in the report. Download the Pompe Disease pipeline report to learn more about the emerging Pompe Disease therapies

Pompe Disease Pipeline Market Drivers

Improving Healthcare Infrastructure
Demand for New and Effective Drugs
Increasing research and development in the gene therapy and enzyme replacement therapy areas

Pompe Disease Pipeline Market Barriers

Lack Of Cost-Effective Treatment

Scope of Pompe Disease Pipeline Drug Insight

Coverage: Global
Key Pompe Disease Companies: Asklepios Biopharmaceutical, GeneCradle Inc, Astellas Gene Therapies, Amicus Therapeutics, M6P Therapeutics, Entrada Therapeutics, Maze Therapeutics, Astellas Gene Therapies, Spark Therapeutics, and others
Key Pompe Disease Therapies: ACTUS-101, GC301, zocaglusagene nuzaparvovec, AT2221, M 021, GYS1 Knockdown Oligonucleotide, MZE 001, AT845, AAV2/8LSPhGAA, SPK-3006, Cipaglucosidase alfa, and others
Pompe Disease Therapeutic Assessment: Pompe Disease current marketed and Pompe Disease emerging therapies
Pompe Disease Market Dynamics: Pompe Disease market drivers and Pompe Disease market barriers

Request for Sample PDF Report for Pompe Disease Pipeline Assessment and clinical trials

Table of Contents

1	Pompe Disease Report Introduction
2	Pompe Disease Executive Summary
3	Pompe Disease Overview
4	Pompe Disease- Analytical Perspective In-depth Commercial Assessment
5	Pompe Disease Pipeline Therapeutics
6	Pompe Disease Late Stage Products (Phase II/III)
7	Pompe Disease Mid Stage Products (Phase II)
8	Pompe Disease Early Stage Products (Phase I)
9	Pompe Disease Preclinical Stage Products
10	Pompe Disease Therapeutics Assessment
11	Pompe Disease Inactive Products
12	Company-University Collaborations (Licensing/Partnering) Analysis
13	Pompe Disease Key Companies
14	Pompe Disease Key Products
15	Pompe Disease Unmet Needs
16	Pompe Disease Market Drivers and Barriers
17	Pompe Disease Future Perspectives and Conclusion
18	Pompe Disease Analyst Views
19	Appendix
20	About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pompe Disease Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Market Dynamics, MOA, ROA by DelveInsight | M6P Therapeutics, Entrada Therapeutics, Maze Therapeutics, Astellas

Brain Tumor Foundation to Present Brain Tumor InfoCon, a Free Informational Program for Patients and Caregivers

Brain Tumor Foundation

October 8 online presentations to feature world’s leading experts discussing topics ranging from neuro-oncology trials to targeting metabolism in glioblastoma and cytokine microdialysis

NEW YORK – The Brain Tumor Foundation (BTF), the nation’s premier non-profit dedicated to providing support and guidance for brain tumor patients and their families, today announced that it will be presenting Brain Tumor InfoCon, a free informational program for patients and caregivers. The online event will feature presentations from some of the world’s leading experts in brain tumor medicine.

Brain Tumor InfoCon will take place on October 8, 2024 from 7:00 PM to 8:00 PM. It will feature six presentations, followed by questions and answers. The program is intended to help patients and caregivers gain a better understanding of the state of brain tumor research and treatment.

“This is a wonderful opportunity to learn about the latest in the brain tumor field,” said Dr. Nelson Oyesiku, BTF President. “The presenters will discuss advanced medical science, but in a relatable way. This promises to be a memorable evening.”

The program features the following presentations:

The Landscape of Neuro-oncology Trails, moderated by Soma Sengupta, MD, PhD, MBA. Dr. Sengupta is Director, Adult Neurosurgical Oncology and Assistant Professor at the Department of Neurosurgery at the University of North Carolina-Chapel Hill. She was nominated as a Committee Member of the British Neuro-Oncology Society (BNOS). BNOS is the leading multi-professional organization in the United Kingdom, dedicated to promoting neuro-oncology research, education, and patient centered care. Dr. Sengupta spent her most formative years in the United Kingdom, where she attended the University of Wales for a Bachelor of Science in Biochemistry. She then went to the University of Cambridge for medical school and a PhD in Biochemistry. During her medical training, Dr. Sengupta was an active participant in immunology research at the Cambridge Institute of Medical Research.

Targeting Metabolism in Glioblastoma, with Dominique Higgins, MD, PhD. Dr. Higgins is Director, Adult Neurosurgical Oncology and Assistant Professor, Department of Neurosurgery at the University of North Carolina-Chapel Hill. He completed a dual MD/PhD program at the Mayo Clinic College of Medicine, appeasing both his interests in medicine and research. While at Mayo, Dr. Higgins spent time in the tumor-focused labs, and eventually completed his PhD thesis on glioblastoma stem cells. During his time at Mayo, Dr. Higgins felt he had found his passion where both his research and clinical interests came together, and he felt he could make a mark on the progress that was being made. He went on to complete his residency training in neurosurgery at Columbia University’s Neurological Institute of New York. He also completed a brain tumor fellowship at the University of Miami, with an emphasis on minimally invasive open and endoscopic surgical treatments for brain tumors. His research focus is the treatment of malignant brain tumors, including glioblastoma. Dr. Higgins received the University of North Carolina School of Medicine DEI Grant and is also the recipient of the American Academy of Neurology Minority Scholars Fellowship and the Mayo Medical Scientist Training Program Bonner Scholarship.

CAR-T Against B7H3 for Glioblastoma, with Yasmeen Rauf, MD. Dr. Rauf is Assistant Professor of Neurology Secondary Appointments: Neurosurgery and Internal Medicine University of North Carolina-Chapel. She is a NIH-funded neuro-oncologist. She did her neurology residency at Ohio State University and neuro-oncology fellowship at the Cleveland Clinic. Her main area of clinical interest is Glioblastoma. Her research interests include finding newer treatments for Glioblastoma. Her current focus of research is CAR-T for Glioblastoma. She runs a phase 1 clinical trial at UNC-Chapel Hill, using CAR-T against B7H3.

Emerging Applications of Focused Ultrasound for Brain Tumors, with Vibhor Krishna, MD. Dr. Krishna is Associate Professor and Vice Chair of Neurological Surgery University of North Carolina-Chapel Hill. He is a board-certified neurosurgeon specializing in functional neurosurgery. As a surgeon-scientist, one of the most exciting areas of his work is the development of focused ultrasound (FUS) technology to treat neurological disorders. He leads an NIH-sponsored research program to optimize the technique of FUS ablation. His research has catalyzed key advancements, including the launch of a Phase-1 clinical trial of FUS in patients with treatment-refractory epilepsy, which has yielded promising initial results. He was deeply involved with the Phase-2 and Phase-3 multicenter trials that secured FDA approval for treating Parkinson’s disease with FUS.

Cytokine Microdialysis, with Edjah Nduom, MD, FAANS. Dr. Nduom is Daniel Louis Barrow Endowed Chair in Neurosurgery Professor, Department of Neurosurgery Emory University School of Medicine. A fellowship-trained and board-certified neurosurgical oncologist, Dr. Nduom’s clinical specialty is the surgical management of brain and spinal cord tumors. He is particularly interested in the safe resection of malignant tumors located in eloquent areas of the brain, the brainstem and spinal cord. Dr. Nduom is a member of the Cancer Immunology Research Program at Winship Cancer Institute of Emory University. He holds numerous positions in national and international medical societies. Notably, he is the Scientific Program Chair and Member at Large for the Congress of Neurological Surgeons, Co-Founder of the Society for Neuro-Oncology Sub-Saharan Africa; Bylaws Chair of the Joint Tumor Section of the American Association of Neurological Surgeons and Congress of Neurological Surgeons. On May 10, 2024, Dr. Nduom was appointed by President Biden to the national Cancer Advisory Board (NCAB). The NCAB complements the Cancer Moonshot and provides guidance to the NCI Director in setting the course for the national cancer research program.

About the Brain Tumor Foundation

The Brain Tumor Foundation (BTF) guides and supports patients and families during the turbulent times when their lives are touched by a brain tumor. BTF educates the public about the need for early detection, while offering support groups, medical referrals and informational events such as Brain Tumor Infocon. BTF Kids, an innovative initiative for pediatric patients and their families is a project of Brain Tumor Foundation.

For more information visit https://www.braintumorfoundation.org or call (212) 489-0600.

To register for Brain Tumor InfoCon, visit https://braintumorfoundation.org/resources/2798-2/ or call (212) 265-2401

Media Contact
Company Name: Brain Tumor Foundation
Contact Person: Schnur Associates
Email: Send Email
Country: United States
Website: https://www.braintumorfoundation.org

Daylight Saving Time by David W. Berner is an Empowering Memoir about the Power of Growing Older

Filled with deeply personal and candid observations, insights and revelations on the act of aging, David W. Berner’s Daylight Saving Time offers a refreshing outlook on the grand adventure of life and the passage of time.

David W. Berner is an award-winning journalist, broadcaster, author, and teacher.

He is the best-selling, award-winning author of fiction, creative nonfiction, memoir, short stories, and poetry. His work includes the novels A Well-Respected Man, The Islander, Night Radio, Sandman, and Rainbow Man, and the nonfiction books Accidental Lessons, Any Road Will Take You There, Walks with Sam, The Consequence of Stars, and Daylight Saving Time. He has won an Eric Hoffer Book Award, Book Excellence Award, NYC Big Book Award, National Association of Independent Writers and Editors Award for Literary Fiction, and the Book of the Year Award from the Chicago Writers Association. He’s also been recognized by the Paris Book Festival, the London Book Festival, The Society of Midland Authors, the Hawthorne Prize, the Royal Dragonfly Awards, and the Readers’ Choice Awards.

David has been honored as the Writer-in-Residence at the Jack Kerouac Project in Orlando, FL and at the Ernest Hemingway Birthplace Home and Museum in Oak Park, IL.

David is a retired associate-professor at Columbia College Chicago, a long-time Chicago broadcast journalist, and now teaches writing at Gotham Writers Workshop of New York City. He writes a regular blog on writing, music, and the arts at The Writer Shed on Medium and personal essays at The Abundance on Substack.

This one-on-one interview shares David W. Berner’s background and experience writing Daylight Saving Time: The Power of Growing Older.

Tell us about Daylight Saving Time: The Power of Growing Older.

When we are young, we think little about growing old.

But time soon catches up with us: the first gray hair, a buckling knee, the purchase of reading glasses, or when a heart attack at the age of 56 rattles your world and reminds you that none of us get out of here alive.

Daylight Saving Time is a meditative and intimate personal narrative on the act of aging where I discover how to accept and revel in the present, when the days that remain are fewer than those that have passed, offering a path for celebrating life’s final chapters.

Through the lessons of seasonal change, the natural world, literature, and spirituality, I offer readers a kind of instruction book on the art of growing older, challenging our society to accept aging and its transformative power. I hope I can share a guiding philosophy on how to discover joy in the time we have left and nourishment in life’s remaining seasons.

What inspired you to write Daylight Saving Time: The Power of Growing Older?

I began writing Daylight Saving Time after experiencing an unexpected heart attack. It was a wake-up call, bringing clarity to life’s most precious purpose and a realization that there were now fewer years ahead of me than behind. I have always believed that the act of aging was in many ways a privilege and that concept inspired me. In writing the book, my hope was to try to understand the unfolding of a life, to document it in the very moments that it was happening, piece by piece, day by day. To help see it, I chose a period of the year that some call the season of light, the space between the shifting of time, between Standard Time and Daylight Saving. It is a man-made concept, but it is also a remarkable period in the yearly ritual of preserving illumination, the darkest time on our calendars; yet we bravely stretch toward the equinox, toward something brighter, something beyond.

Like aging itself, what ended up in the book were small increments of a path that is nearly unnoticeable—little surprises, unforeseen awakenings, frightening experiences, moments of celebration and resignation, sorrow and delight—mixing like the chemicals of a mad scientist.

The book shares my personal journey, however, the philosophies, ideas and principles introduced are universal. I hope it will resonate with many around the world, no matter the age.

What is one message you would like readers to remember?

I would like readers to see that aging is a privilege, a kind of adventure that should be embraced.

There are many cliches about accepting one’s age: “Age is only a number,” “You’re only as old as you feel,” and so on.

Daylight Saving Time is not a book that simply reiterates those old adages. Nor is it a self-help manual. Instead, the book takes it a step further by asking an important question: How do you plan to revel in the final chapters of your life?

Purchasing the Book

Daylight Saving Time: The Power of Growing Older (O-Books/Collective Ink) has received positive reviews from well-known experts, authors, and reviewers around the world. Book Excellence writes, “An authentic and touching memoir that delves into the complexities of aging, offering profound insights and heartfelt reflections on life’s journey.” In addition, Ryan Lindner, author of The Half-Known Life writes, “A touching, introspective exploration of life as we age…Daylight Saving Time is an exploration of what it means to truly live and grasp the beauty of life before it’s gone.”

The book is available for sale on Amazon, Barnes & Noble, Apple iBooks, Kobo, Nook, Google Play, and other online bookstores. Readers are encouraged to purchase their copy today: https://www.amazon.com/Daylight-Saving-Time-Power-Growing/dp/1803415118

To connect with David and learn more about his work, visit: www.davidwberner.com. You can also find him on Facebook and Instagram.

Media Contact
Company Name: Author News Network
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: authornewsnetwork.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Daylight Saving Time by David W. Berner is an Empowering Memoir about the Power of Growing Older

Abdominal Aortic Aneurysm Pipeline Forecast 2024: FDA Approvals, Therapies, and Leading Companies involved by DelveInsight | Merck Serono, AstraZeneca, Endologix LLC, Cardinal Health, Cook Medical

Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Abdominal Aortic Aneurysm pipeline constitutes key companies continuously working towards developing Abdominal Aortic Aneurysm treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Abdominal Aortic Aneurysm Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Abdominal Aortic Aneurysm Market.

The Abdominal Aortic Aneurysm Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Abdominal Aortic Aneurysm Pipeline Report:

Companies across the globe are diligently working toward developing novel Abdominal Aortic Aneurysm treatment therapies with a considerable amount of success over the years. Abdominal Aortic Aneurysm Key players such as – Merck Serono, AstraZeneca, Endologix LLC, Cardinal Health, Cook Medical, W. L. Gore & Associates, Inc., Medtronic, MicroPort Scientific Corporation, Artivion, Inc., Lifetech Scientific (Shenzhen) Co., Ltd., Lombard Medical, Endologix LLC, Latecba SA, Nectero Medical, Cardiatis, SA, Hangzhou Endonom Medtech Co., Ltd., and others, and others, are developing therapies for the Abdominal Aortic Aneurysm treatment

Abdominal Aortic Aneurysm Emerging therapies such as – Ticagrelor, Metformin Glucophage, Abdominal Aortic Aneurysm Stent Graft System, Fenestrated AlturaTM FEVAR Stent Graft, Seta Latecba Stent Grafts, Nectero EAST®, Bifurcated MFM®, and others, and others are expected to have a significant impact on the Abdominal Aortic Aneurysm market in the coming years.
In January 2024, Arizona-based Nectro Medical has initiated a Phase II/III trial evaluating the safety and efficacy of its endovascular aneurysm stabilisation treatment (Nectero EAST). Nectero EAST is a single-use, endovascular system made up of a dual-balloon delivery catheter and stabiliser mixture of pentagalloyl glucose (PGG). The PGG, when administered locally, can bind to elastin and collagen to potentially strengthen the aortic wall. Animal studies have shown that PGG can hinder the development of abdominal aortic aneurysm (AAA).

Abdominal Aortic Aneurysm Overview

Abdominal Aortic Aneurysm (AAA) is a localized enlargement of the abdominal aorta such that the diameter is greater than 3 cm or more than 50% larger than usual. It occurs when atherosclerosis or plaque buildup causes the walls of the abdominal aorta to become weak and bulge outward like a balloon.

Get a Free Sample PDF Report to know more about Abdominal Aortic Aneurysm Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/abdominal-aortic-aneurysm-pipeline-insight

Abdominal Aortic Aneurysm Pipeline Therapeutics Assessment

Abdominal Aortic Aneurysm Assessment by Product Type
Abdominal Aortic Aneurysm By Stage and Product Type
Abdominal Aortic Aneurysm Assessment by Route of Administration
Abdominal Aortic Aneurysm By Stage and Route of Administration
Abdominal Aortic Aneurysm Assessment by Molecule Type
Abdominal Aortic Aneurysm by Stage and Molecule Type

DelveInsight’s Abdominal Aortic Aneurysm Report covers around products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Some of the key companies in the Abdominal Aortic Aneurysm Therapeutics Market include:

Key companies developing therapies for Abdominal Aortic Aneurysm treatment are – CARDIATIS S.A., CARDINAL HEALTH, INC., COOK MEDICAL, INC., ENDOLOGIX, INC., jotec gmbh, LOMBARD MEDICAL, INC., MEDTRONIC PLC, nano endoluminal sa, TERUMO CORPORATION, W. L. GORE & ASSOCIATES, INC., and others.

Download Sample PDF Report to know more about Abdominal Aortic Aneurysm drugs and therapies

Emerging Abdominal Aortic Aneurysm Drugs and devices Under Different Phases of Clinical Development Include:

Metformin Glucophage: Merck Serono
Ticagrelor: AstraZeneca
Abdominal Aortic Aneurysm Stent Graft System: Lifetech Scientific
Fenestrated AlturaTM FEVAR Stent Graft: Lombard Medical
Seta Latecba Stent Grafts: Latecba SA
Nectero EAST®: Nectero Medical
Bifurcated MFM®: Cardiatis

Abdominal Aortic Aneurysm Pipeline Analysis:

The Abdominal Aortic Aneurysm pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Abdominal Aortic Aneurysm with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Abdominal Aortic Aneurysm Treatment.
Abdominal Aortic Aneurysm key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Abdominal Aortic Aneurysm Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Abdominal Aortic Aneurysm market.

Further Abdominal Aortic Aneurysm product details are provided in the report. Download the Abdominal Aortic Aneurysm pipeline report to learn more about the emerging Abdominal Aortic Aneurysm therapies

Scope of Abdominal Aortic Aneurysm Pipeline Drug Insight

Coverage: Global
Key Abdominal Aortic Aneurysm Companies: Merck Serono, AstraZeneca, Endologix LLC, Cardinal Health, Cook Medical, W. L. Gore & Associates, Inc., Medtronic, MicroPort Scientific Corporation, Artivion, Inc., Lifetech Scientific (Shenzhen) Co., Ltd., Lombard Medical, Endologix LLC, Latecba SA, Nectero Medical, Cardiatis, SA, Hangzhou Endonom Medtech Co., Ltd., and others, and others
Key Abdominal Aortic Aneurysm Therapies: Ticagrelor, Metformin Glucophage, Abdominal Aortic Aneurysm Stent Graft System, Fenestrated AlturaTM FEVAR Stent Graft, Seta Latecba Stent Grafts, Nectero EAST®, Bifurcated MFM®, and others, and others
Abdominal Aortic Aneurysm Therapeutic Assessment: Abdominal Aortic Aneurysm current marketed and Abdominal Aortic Aneurysm emerging therapies
Abdominal Aortic Aneurysm Market Dynamics: Abdominal Aortic Aneurysm market drivers and Abdominal Aortic Aneurysm market barriers

Request for Sample PDF Report for Abdominal Aortic Aneurysm Pipeline Assessment and clinical trials

Table of Contents

1	Abdominal Aortic Aneurysm Report Introduction
2	Abdominal Aortic Aneurysm Executive Summary
3	Abdominal Aortic Aneurysm Overview
4	Abdominal Aortic Aneurysm- Analytical Perspective In-depth Commercial Assessment
5	Abdominal Aortic Aneurysm Pipeline Therapeutics
6	Abdominal Aortic Aneurysm Late Stage Products (Phase II/III)
7	Abdominal Aortic Aneurysm Mid Stage Products (Phase II)
8	Abdominal Aortic Aneurysm Early Stage Products (Phase I)
9	Abdominal Aortic Aneurysm Preclinical Stage Products
10	Abdominal Aortic Aneurysm Therapeutics Assessment
11	Abdominal Aortic Aneurysm Inactive Products
12	Company-University Collaborations (Licensing/Partnering) Analysis
13	Abdominal Aortic Aneurysm Key Companies
14	Abdominal Aortic Aneurysm Key Products
15	Abdominal Aortic Aneurysm Unmet Needs
16	Abdominal Aortic Aneurysm Market Drivers and Barriers
17	Abdominal Aortic Aneurysm Future Perspectives and Conclusion
18	Abdominal Aortic Aneurysm Analyst Views
19	Appendix
20	About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Abdominal Aortic Aneurysm Pipeline Forecast 2024: FDA Approvals, Therapies, and Leading Companies involved by DelveInsight | Merck Serono, AstraZeneca, Endologix LLC, Cardinal Health, Cook Medical

Alpha Thalassemia Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances, MOA, ROA by DelveInsight | Genmedicn Biopharma Ltd., Bristol-Myers Squibb, Agios Pharma

(Las Vegas, Nevada, United States) As per DelveIns ight’s assessment, globally, Alpha Thalassemia pipeline constitutes 4+ key companies continuously working towards developing 5+ Alpha Thalassemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Alpha Thalassemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Alpha Thalassemia Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Alpha Thalassemia Market.

Some of the key takeaways from the Alpha Thalassemia Pipeline Report:

Companies across the globe are diligently working toward developing novel Alpha Thalassemia treatment therapies with a considerable amount of success over the years.
Alpha Thalassemia companies working in the treatment market are Forma Therapeutics, Inc., Genmedicn Biopharma Ltd., Bristol-Myers Squibb, Agios Pharmaceuticals, and others, are developing therapies for the Alpha Thalassemia treatment

Emerging Alpha Thalassemia therapies in the different phases of clinical trials are- Etavopivat tablets, GMCN-508A, Luspatercept, Mitapivat, and others are expected to have a significant impact on the Alpha Thalassemia market in the coming years.
In January 2024, Agios Pharmaceuticals reported positive outcomes in a Phase III ENERGIZE trial of mitapivat for patients with non-transfusion-dependent alpha- or beta-thalassemia, meeting primary and two key secondary endpoints. The company intends to seek regulatory approval for mitapivat as a thalassemia treatment by year-end, incorporating data from the second Phase III ENERGISE-T study (NCT04770779) for adults with transfusion-dependent alpha-thalassemia or beta-thalassemia.

Alpha Thalassemia Overview

Alpha thalassemia is a genetic disorder characterized by a deficiency in the production of alpha globin chains, which are essential components of hemoglobin, the protein in red blood cells that carries oxygen throughout the body. This deficiency results in a reduced amount of hemoglobin and red blood cells, leading to anemia.

Get a Free Sample PDF Report to know more about Alpha Thalassemia Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/alpha-thalassemia-pipeline-insight-pipeline-insight

Emerging Alpha Thalassemia Drugs Under Different Phases of Clinical Development Include:

Etavopivat tablets: Forma Therapeutics, Inc.
GMCN-508A: Genmedicn Biopharma Ltd.
Luspatercept: Bristol-Myers Squibb
Mitapivat: Agios Pharmaceuticals

Alpha Thalassemia Route of Administration

Alpha Thalassemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Alpha Thalassemia Molecule Type

Alpha Thalassemia Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type

Alpha Thalassemia Pipeline Therapeutics Assessment

Alpha Thalassemia Assessment by Product Type
Alpha Thalassemia By Stage and Product Type
Alpha Thalassemia Assessment by Route of Administration
Alpha Thalassemia By Stage and Route of Administration
Alpha Thalassemia Assessment by Molecule Type
Alpha Thalassemia by Stage and Molecule Type

DelveInsight’s Alpha Thalassemia Report covers around 5+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Alpha Thalassemia product details are provided in the report. Download the Alpha Thalassemia pipeline report to learn more about the emerging Alpha Thalassemia therapies

Alpha Thalassemia Pipeline Analysis:

The Alpha Thalassemia pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Alpha Thalassemia with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alpha Thalassemia Treatment.
Alpha Thalassemia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Alpha Thalassemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Alpha Thalassemia market.

Download Sample PDF Report to know more about Alpha Thalassemia drugs and therapies

Alpha Thalassemia Pipeline Market Drivers

Increasing Prevalence genetic disorders and advancement in healthcare technologies, growing demand for treatment for Alpha Thalassemia are some of the important factors that are fueling the Alpha Thalassemia Market.

Alpha Thalassemia Pipeline Market Barriers

However, lack of available appropriate treatments and procedures, high cost of treatment and other factors are creating obstacles in the Alpha Thalassemia Market growth.

Scope of Alpha Thalassemia Pipeline Drug Insight

Coverage: Global
Key Alpha Thalassemia Companies: Forma Therapeutics, Inc., Genmedicn Biopharma Ltd., Bristol-Myers Squibb, Agios Pharmaceuticals, and others
Key Alpha Thalassemia Therapies: Etavopivat tablets, GMCN-508A, Luspatercept, Mitapivat, and others
Alpha Thalassemia Therapeutic Assessment: Alpha Thalassemia current marketed and Alpha Thalassemia emerging therapies
Alpha Thalassemia Market Dynamics: Alpha Thalassemia market drivers and Alpha Thalassemia market barriers

Request for Sample PDF Report for Alpha Thalassemia Pipeline Assessment and clinical trials

Table of Contents

1. Alpha Thalassemia Report Introduction

2. Alpha Thalassemia Executive Summary

3. Alpha Thalassemia Overview

4. Alpha Thalassemia- Analytical Perspective In-depth Commercial Assessment

5. Alpha Thalassemia Pipeline Therapeutics

6. Alpha Thalassemia Late Stage Products (Phase II/III)

7. Alpha Thalassemia Mid Stage Products (Phase II)

8. Alpha Thalassemia Early Stage Products (Phase I)

9. Alpha Thalassemia Preclinical Stage Products

10. Alpha Thalassemia Therapeutics Assessment

11. Alpha Thalassemia Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Alpha Thalassemia Key Companies

14. Alpha Thalassemia Key Products

15. Alpha Thalassemia Unmet Needs

16 . Alpha Thalassemia Market Drivers and Barriers

17. Alpha Thalassemia Future Perspectives and Conclusion

18. Alpha Thalassemia Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Alpha Thalassemia Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances, MOA, ROA by DelveInsight | Genmedicn Biopharma Ltd., Bristol-Myers Squibb, Agios Pharma